Novopharm
Executive Summary
Files ANDA for Form I ranitidine, equivalent to Glaxo's Zantac. Glaxo markets Form 2, for which Novopharm also has a pending ANDA. The form 2 patent runs until 2002 and Novopharm is challenging it. The Form 1 patent expires December 1995. Novopharm is the second company to file an ANDA for that version of the ulcer drug. Geneva filed its ANDA in March, and Glaxo sued the company in April